Latest:
Joan Lockhart on Fostering Oncology Nursing Education
Joan Such Lockhart, PhD, RN, AOCN, FAAN, from the Duquesne University School of Nursing, discusses resources currently available to help strengthen the oncology training of nurses.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Joanne Blum, MD, PhD
Latest:
Dr. Blum on Takeaways from ABC Trials for Breast Cancer
Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.
Joanne E. Filicko-O’Hara, MD
Latest:
Day in the Life of an Oncology/Hematology Fellowship Program Director
Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.
Jody Sheehan Garey, PharmD
Latest:
Compatibility Check: Can Precision Medicine and Pathways Co-Exist?
One of the most widely talked about trends in healthcare is precision
medicine, which uses detailed genetic information about a patient’s cancer to
more precisely treat the disease, effectively targeting the tumor. This heightened
awareness raises an important question: are precision medicine and
pathways compatible?
Joe OSullivan, MD
Latest:
Dr. O'Sullivan on Safety Profile of Radium-223
Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.
Joel Neal, MD
Latest:
Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLC
Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).
Joel Silver, MD
Latest:
Dr. Silver Talks About Advances in Treatment of Hematological Cancers
Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.